Acromegaly is typically caused by benign pituitary tumors that oversecrete growth hormone, which leads to elevated levels of IGF-1, producing the clinical signs and symptoms that characterize acromegaly.2 These effects may manifest slowly over the course of a decade or more.2
Veldoreotide extended release is a pre-clinical next-generation somatostatin analog under development by Strongbridge for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation.
The safety and efficacy of veldoreotide for treatment of acromegaly have not been established.
© 2019 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Dublin Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MLR-0010 V15 01/2019